Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Type C lectin domain protein 9A(CLEC9A) is a type II transmembrane pattern recognition receptor encoded by CLEC9A gene, which is specifically expressed in a subset of classical type 1 dendritic cells (cDC1) and located on the surface of dendritic cell membrane and endosomal vesicles. Unlike other type C lectin receptors that recognize pathogens, CLEC9A can specifically recognize filamentous actin released by necrotic injury cells and tumor cells, and perceive it as endogenous injury-related molecular patterns (DAMPs). After the receptor binds to the ligand, the endocytosis process is started, and CLEC9A transports the internalized tumor components to the cross-presenting endosome, completing the loading of MHC class I molecules of tumor antigens, thus activating the anti-tumor adaptive immunity mediated by CD8⁺ cytotoxic T cells. Under normal tissue steady state, the basic expression level of CLEC9A is low, which can avoid abnormal uptake of its own tissue fragments and maintain peripheral immune tolerance; The actin ligand released by a large number of necrotic cells in tumor microenvironment can continuously activate CLEC9A signal and induce a powerful anti-tumor immune response. Other myeloid lectins can't compensate the cross-presentation function of CLEC9A, which relies on cDC1. Knocking out CLEC9A will significantly weaken the cross-sensitization ability of tumor and accelerate the malignant progress of tumor. The antigen delivery system targeting CLEC9A can greatly improve the effect of tumor immunotherapy, making it the core target of dendritic cell immune mechanism research and tumor vaccine development.
CLEC9A is anchored in the cell membrane of cDC1, which mainly plays the role of injury perception and antigen uptake, and relies on extracellular C-lectin domain to specifically bind cytoskeleton actin exposed by necrotic cells. Its recognition characteristics of endogenous damage ligands are different from those of CLR family members who traditionally perceive microorganisms, and constitute a unique tumor immune monitoring receptor pathway in the body. CLEC9A-mediated endocytosis can link the signal of tissue necrosis with the cross-presentation mechanism of MHC class I antigen, and dynamically regulate the balance between anti-tumor immunity and self-tolerance according to the degree of tissue injury. This molecule is involved in key immune processes such as cross-sensitization of solid tumor antigen and anti-virus CD8 T cell response, and the loss of CLEC9A function will completely block the efficient tumor-specific CD8 T cell activation. Therefore, CLEC9A is the key research target of dendritic cell receptor research and tumor immunotherapy screening.
Fig. 1 Graphical Abstract Schematic of CLEC9A-targeted CBP-12 tumor vaccine triggering Syk-dependent antigen cross-presentation, IL-21 secretion and cytotoxic T cell-mediated tumor elimination.1
The biological functions of CLEC9A are focused on actin ligand binding and MHC I antigen cross-presentation:
Creative Biolabs offers high-quality CLEC9A proteins through optimized eukaryotic expression systems, including full-length dendritic cell receptor and isolated lectin ligand-binding domain variants. These products retain native actin-binding endocytic activity, suitable for antigen delivery and dendritic cell immunotherapy screening assays. All CLEC9A proteins undergo strict quality control to ensure consistent performance and reliable application across immunology research platforms.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
Creative Biolabs provides custom-engineered CLEC9A stable cell lines, including cDC1-mimic overexpression and blank control models. These cell lines are optimized for dendritic lectin receptor profiling and cross-presentation functional analysis. Each cell line undergoes stringent validation to ensure stable expression profiles and consistent functional performance in diverse experimental contexts.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
High-specificity recombinant antibodies targeting CLEC9A are developed via advanced antibody engineering technologies, with no cross-reactivity with other dendritic C-type lectins. These antibodies are validated for cDC1 membrane/endosome localization detection and lymphoid tissue profiling, and can be combined with MHC I detection reagents to analyze antigen cross-presentation complexes in primary dendritic cell models.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
Beyond catalog products, Creative Biolabs offers specialized custom services for CLEC9A research:
CLEC9A is a cDC1-restricted C-type lectin receptor that binds necrotic actin to mediate tumor antigen cross-presentation for CD8+ T cell activation.
CLEC9A is a unique target for dendritic cell antigen delivery to boost anti-tumor cytotoxic immune responses in immunotherapy.
No, all CLEC9A products and services are strictly for research use only, not intended for clinical immunotherapy trials.
Offerings include full-length CLEC9A dendritic receptor proteins, isoform-specific detection antibodies and custom stable cell lines for antigen presentation research.
CLEC9A proteins are validated via filamentous actin binding and antigen cross-presentation functional testing.
